SCILEX HOLDING CO (SCLX) Stock Overview
NASDAQ:SCLX - US80880W2052 - Common Stock
SCLX Key Statistics, Chart & Performance
The current stock price of SCLX is 18.87 USD. In the past month the price increased by 57.78%. In the past year, price decreased by -55.81%.
SCLX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.07 | 673.58B | ||
| JNJ | JOHNSON & JOHNSON | 17.93 | 431.79B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.69 | 253.19B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.24 | 251.05B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.35 | 245.81B | ||
| MRK | MERCK & CO. INC. | 11.35 | 218.23B | ||
| PFE | PFIZER INC | 7.63 | 147.14B | ||
| SNY | SANOFI-ADR | 11.64 | 125.24B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.12 | 97.54B | ||
| GSK | GSK PLC-SPON ADR | 8.95 | 81.01B | ||
| ZTS | ZOETIS INC | 25.18 | 69.41B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 53.52 | 49.02B |
Related stock screener links
About SCLX
Company Profile
Scilex Holding Co is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Palo Alto, California and currently employs 111 full-time employees. The company went IPO on 2021-01-11. Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
Company Info
SCILEX HOLDING CO
960 San Antonio Road
Palo Alto CALIFORNIA US
Employees: 111
Phone: 16505164310
SCILEX HOLDING CO / SCLX FAQ
What is the stock price of SCILEX HOLDING CO today?
The current stock price of SCLX is 18.87 USD. The price increased by 10.09% in the last trading session.
What is the ticker symbol for SCILEX HOLDING CO stock?
The exchange symbol of SCILEX HOLDING CO is SCLX and it is listed on the Nasdaq exchange.
On which exchange is SCLX stock listed?
SCLX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SCILEX HOLDING CO stock?
8 analysts have analysed SCLX and the average price target is 499.8 USD. This implies a price increase of 2548.65% is expected in the next year compared to the current price of 18.87. Check the SCILEX HOLDING CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SCILEX HOLDING CO worth?
SCILEX HOLDING CO (SCLX) has a market capitalization of 131.34M USD. This makes SCLX a Micro Cap stock.
How many employees does SCILEX HOLDING CO have?
SCILEX HOLDING CO (SCLX) currently has 111 employees.
What are the support and resistance levels for SCILEX HOLDING CO (SCLX) stock?
SCILEX HOLDING CO (SCLX) has a support level at 17.14 and a resistance level at 20.87. Check the full technical report for a detailed analysis of SCLX support and resistance levels.
Is SCILEX HOLDING CO (SCLX) expected to grow?
The Revenue of SCILEX HOLDING CO (SCLX) is expected to grow by 84.5% in the next year. Check the estimates tab for more information on the SCLX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SCILEX HOLDING CO (SCLX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SCLX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SCLX, evaluating the profitability, health, valuation and growth aspects
- SCILEX HOLDING CO (SCLX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SCILEX HOLDING CO (SCLX) Sales and EPS estimates to see what analysts future expectations are.
- SCILEX HOLDING CO (SCLX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SCILEX HOLDING CO (SCLX) Insider and Institutional Ownership to learn about the owners and their transactions.
- SCILEX HOLDING CO (SCLX) Stock Chart to make your own analysis
- SCILEX HOLDING CO (SCLX) Latest news and press-releases to stay up to date.
Does SCILEX HOLDING CO (SCLX) stock pay dividends?
SCLX does not pay a dividend.
When does SCILEX HOLDING CO (SCLX) report earnings?
SCILEX HOLDING CO (SCLX) will report earnings on 2026-01-16, after the market close.
What is the Price/Earnings (PE) ratio of SCILEX HOLDING CO (SCLX)?
SCILEX HOLDING CO (SCLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.1).
What is the Short Interest ratio of SCILEX HOLDING CO (SCLX) stock?
The outstanding short interest for SCILEX HOLDING CO (SCLX) is 8.21% of its float. Check the ownership tab for more information on the SCLX short interest.
SCLX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SCLX. When comparing the yearly performance of all stocks, SCLX is one of the better performing stocks in the market, outperforming 97.8% of all stocks.
SCLX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SCLX. SCLX has a bad profitability rating. Also its financial health evaluation is rather negative.
SCLX Financial Highlights
Over the last trailing twelve months SCLX reported a non-GAAP Earnings per Share(EPS) of -7.1. The EPS increased by 85.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -164.82% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SCLX Forecast & Estimates
8 analysts have analysed SCLX and the average price target is 499.8 USD. This implies a price increase of 2548.65% is expected in the next year compared to the current price of 18.87.
For the next year, analysts expect an EPS growth of 80.66% and a revenue growth 84.5% for SCLX